RecruitingNot ApplicableNCT03962920

Personalized Treatment of Urogenital Cancers Depends on the Microbiome

Sponsor

Zealand University Hospital

Enrollment

28 participants

Start Date

May 1, 2020

Study Type

INTERVENTIONAL

Conditions

Microbial Disease

Summary

This is a randomized controlled trial where patients undergoing surgical treatment for urogenital cancers will be randomized in a two arms study: surgical treatment + antibiotics OR surgical treatment + placebo.

Eligibility

Min Age: 40 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and a drug called Tigecycline 50 MG for people with microbial disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 40 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTigecycline 50 MG

Local instillation of drug directly to the tumour tissue

OTHERPlacebo

Local instillation of sterile water directly to the tumour tissue

Locations(1)

Zealand University Hospital

Roskilde, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03962920

Related Trials

Microbiome and Malnutrition in Pregnancy

NCT049921042 locations